Triple Therapy for Neovascular Age-Related Macular Degeneration
Author Information
Author(s): Ahmadieh Hamid, Taei Ramin, Soheilian Masoud, Riazi-Esfahani Mohammad, Karkhaneh Reza, Lashay Alireza, Azarmina Mohsen, Dehghan Mohammad Hossein, Moradian Siamak
Primary Institution: Ophthalmic Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Hypothesis
To evaluate the efficacy of triple therapy consisting of single-session photodynamic therapy, intravitreal bevacizumab, and intravitreal triamcinolone as initial pulse therapy followed by repeat intravitreal bevacizumab injections for maintenance treatment in neovascular age-related macular degeneration.
Conclusion
Initial pulse triple therapy consisting of single-session PDT combined with IVB and IVT improves vision and reduces central macular thickness in neovascular AMD.
Supporting Evidence
- Mean BCVA improved from 0.74 logMAR before treatment to 0.52 logMAR after 12 weeks.
- Mean central macular thickness reduced from 395μ to 217μ at week 6 after treatment.
- Visual acuity improvement was maintained during the follow-up period.
Takeaway
This study found that a special treatment combining three therapies can help people with a certain eye problem see better and have healthier eyes.
Methodology
A prospective interventional case series where patients underwent pulse therapy with single-session PDT followed by intravitreal injections of bevacizumab and triamcinolone.
Limitations
The study had a small number of patients and lacked control groups, making it difficult to generalize the results.
Participant Demographics
17 patients with a mean age of 67.6 years, including 7 males and 10 females.
Statistical Information
P-Value
p=0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website